1
|
Nakamura K, Suzuki Y, Goto K, Yamaguchi S, Hiramitsu M. Antihypertensive and Vasorelaxant Effects of Citric Acid and Lemon Juice in Spontaneously Hypertensive Rats: In Vivo and Ex Vivo Studies. Nutrients 2023; 15:3849. [PMID: 37686881 PMCID: PMC10489964 DOI: 10.3390/nu15173849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 09/01/2023] [Accepted: 09/01/2023] [Indexed: 09/10/2023] Open
Abstract
Hypertension is a key risk factor for heart, brain, and kidney disease development. Fruit consumption has been associated with a decrease in blood pressure. Lemon juice, which contains antihypertensive compounds, may exert antihypertensive effects. However, no research has verified the antihypertensive effects of citric acid, the most abundant ingredient in lemon juice. In the present study, we demonstrated the antihypertensive effects of citric acid and lemon juice by performing single oral administration tests and the aortic ring assay using spontaneously hypertensive rats (SHRs). Single oral doses of both agents markedly reduced the systolic and diastolic blood pressures in the SHRs. In addition, both these agents relaxed the thoracic aorta from the SHRs; however, these effects were notably attenuated by the removal of the aortic endothelium. Orally administered citric acid was rapidly absorbed and metabolized in vivo. Among the functional compounds in lemon juice, citric acid was identified as the primary antihypertensive component. Although more detailed studies are required to validate our findings, the novel functional attributes of citric acid can achieve the normalization of blood pressure when it is consumed via diet.
Collapse
Affiliation(s)
- Kozo Nakamura
- Department of Science and Technology, Graduate School of Medicine, Science and Technology, Shinshu University, 8304, Minamiminowa, Nagano 399-4598, Japan; (Y.S.); (K.G.)
- Department of Bioscience and Biotechnology, Faculty of Agriculture, Shinshu University, 8304, Minamiminowa, Nagano 399-4598, Japan;
- Institute of Agriculture, Academic Assembly, Shinshu University, 8304, Minamiminowa, Nagano 399-4598, Japan
| | - Yumiko Suzuki
- Department of Science and Technology, Graduate School of Medicine, Science and Technology, Shinshu University, 8304, Minamiminowa, Nagano 399-4598, Japan; (Y.S.); (K.G.)
| | - Kazuma Goto
- Department of Science and Technology, Graduate School of Medicine, Science and Technology, Shinshu University, 8304, Minamiminowa, Nagano 399-4598, Japan; (Y.S.); (K.G.)
| | - Shohei Yamaguchi
- Department of Bioscience and Biotechnology, Faculty of Agriculture, Shinshu University, 8304, Minamiminowa, Nagano 399-4598, Japan;
| | - Masanori Hiramitsu
- Pokka Sapporo Food and Beverage Ltd., 10, Okatome, Yaizu, Shizuoka 425-0013, Japan;
| |
Collapse
|
2
|
Park S, Lee KH, Choi H, Jang G, Kang WS, Kim E, Kim JS, Na CS, Kim S. Combined antihypertensive effect of unripe Rubus coreanus Miq. and Dendropanax morbiferus H. Lév. Extracts in 1 kidney-1 clip hypertensive rats and spontaneously hypertensive rats. BMC Complement Med Ther 2021; 21:271. [PMID: 34711215 PMCID: PMC8555169 DOI: 10.1186/s12906-021-03438-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Accepted: 10/08/2021] [Indexed: 11/23/2022] Open
Abstract
Background We previously showed that enzymatically hydrolyzed Dendropanax morbiferus H. Lév. leaf (Hy-DP) and unripe Rubus coreanus Miq. (5-uRCK) extracts exhibit potent vasodilator effects on isolated aortic rings from rats partly through endothelium-dependent and endothelium-independent mechanisms. These two extracts have different mechanisms of action; however, their combined effect on antihypertensive activity has not been explored. Methods The present study aims to investigate the effect of a chronic optimized mixture (HDR-2, composed of Hy-DP and 5-uRCK in a 2:1 mass ratio) on vascular tension and blood pressure in two different hypertensive rat models. Results The results showed that HDR-2 concentration-dependently relaxed endothelium-intact and endothelium-denuded aortic rings precontracted with phenylephrine. Antihypertensive effects were assessed in vivo on a 1 kidney-1 clip (1 K-1C) rat model of hypertension and spontaneously hypertensive rats (SHRs). Acute HDR-2 treatment significantly decreased systolic blood pressure (SBP) 3 h posttreatment in both models. Chronic HDR-2 administration also significantly decreased SBP in the hypertensive rat models. Moreover, HDR-2 increased eNOS protein expression and phosphorylation levels in the aorta. Conclusion Chronic HDR-2 administration may effectively improve vascular function by decreasing plasma angiotensin-converting enzyme (ACE) activity and AngII levels. HDR-2 significantly improved acetylcholine (ACh)-induced aortic endothelium-dependent relaxation and affected sodium nitroprusside (SNP)-induced endothelium-independent relaxation in SHRs.
Collapse
Affiliation(s)
- Soyi Park
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., 257, Jebong-ro, Buk-gu, Gwangju, 61239, South Korea
| | - Ki Hoon Lee
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., 257, Jebong-ro, Buk-gu, Gwangju, 61239, South Korea
| | - Hakjoon Choi
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., 257, Jebong-ro, Buk-gu, Gwangju, 61239, South Korea
| | - Goeun Jang
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., 257, Jebong-ro, Buk-gu, Gwangju, 61239, South Korea
| | - Wan Seok Kang
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., 257, Jebong-ro, Buk-gu, Gwangju, 61239, South Korea
| | - Eun Kim
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., 257, Jebong-ro, Buk-gu, Gwangju, 61239, South Korea
| | - Jin Seok Kim
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., 257, Jebong-ro, Buk-gu, Gwangju, 61239, South Korea
| | - Chang-Su Na
- College of Korean Medicine, Dongshin University, 185 Geonjae-ro, Naju-si, Jeollanam-do, 58245, Republic of Korea
| | - Sunoh Kim
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., 257, Jebong-ro, Buk-gu, Gwangju, 61239, South Korea.
| |
Collapse
|
3
|
Laxative Effects of a Standardized Extract of Dendropanax morbiferus H. Léveille Leaves on Experimental Constipation in Rats. Medicina (B Aires) 2021; 57:medicina57111147. [PMID: 34833365 PMCID: PMC8619072 DOI: 10.3390/medicina57111147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 10/18/2021] [Accepted: 10/20/2021] [Indexed: 11/17/2022] Open
Abstract
Background and Objectives: This study aimed at investigating the laxative effects of a standardized aqueous extract of Dendropanax morbiferus H. Lév. on two different constipation rat models. Materials and Methods: Animal studies were conducted with low-fiber diet-induced and loperamide-induced constipation animal models, and isolated colons were used in ex vivo analysis to determine the changes in colonic motility caused by D. morbiferus H. Lév. leaf extract (DPL). Results: The results showed that DPL administration significantly improved certain reduced fecal parameters (number, weight, and water content of the stools) in a both low-fiber diet and loperamide-induced constipation models without adverse effects of diarrhea. The laxative effect of DPL was confirmed to improve the charcoal excretion time upon DPL treatment in a low-fiber diet or loperamide-induced constipation model through gastrointestinal (GI) motility evaluation using the charcoal meal test. In addition, when DPL was administered to RAW264.7 cells and loperamide-induced constipation model rats, the production of prostaglandin E2 (PGE2) increased significantly in cells and tissue. Furthermore, DPL dose-dependently stimulated the spontaneous contractile amplitude and frequency of the isolated rat colon. Conclusion: Although our study did not provide information on the acute or chronic toxicity of DPL, our results demonstrated that DPL can effectively promote defecation frequency and rat colon contraction, providing scientific evidence to support the use of DPL as a therapeutic application. However, further toxicity studies of DPL are needed prior to the initiation of clinical trials and clinical applications.
Collapse
|
4
|
Antihyperuricemic Effect of Dendropanax morbifera Leaf Extract in Rodent Models. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2021; 2021:3732317. [PMID: 34335806 PMCID: PMC8324340 DOI: 10.1155/2021/3732317] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 07/08/2021] [Accepted: 07/16/2021] [Indexed: 12/11/2022]
Abstract
Dendropanax morbifera is a well-known traditional medicine used in China and Korea to treat intestinal disorders, urosis, diuresis, and chronic glomerulonephritis. Hyperuricemia is a metabolic disorder characterized by a high uric acid level in serum due to an imbalance between uric acid production and excretion and causes gout. Recently, the prevalence of hyperuricemia worldwide has been continuously increasing. Xanthine oxidase (XOD) inhibitors (allopurinol (ALP) and febuxostat) and uricosuric agents (benzbromarone and probenecid) are used to treat hyperuricemia clinically. However, because these drugs are poorly tolerated and cause side effects, such as kidney diseases, hepatotoxicity, gastrointestinal symptoms, and hypersensitivity syndrome, only a limited number of drugs are available. We investigated the antihyperuricemic effects of Dendropanax morbifera leaf ethanol extract (DMLE) and its underlying mechanisms of action through in vitro and in vivo studies. We evaluated uric acid levels in serum and urine, and xanthine oxidase (XOD) inhibition activity in the serum and liver tissue of a hyperuricemic rat model of potassium oxonate (PO)-induced hyperuricemic rats. In vitro study, XOD-inhibitory activity was the lowest among the test substances at the IC50 of ALP. However, the IC50 of DMLE-70 was significantly low compared with that of other DMLEs (p < 0.05). In PO-induced hyperuricemic rats, uric acid (UA) levels in serum and urine were significantly reduced in all DMLE-70 and allopurinol-treated (ALT) groups than in the PC group (p < 0.05). UA levels in urine were lower than those in serum in all DME groups. In PO-induced hyperuricemic rats, DMEE-200 reduced UA concentration in serum and increased UA excretion in the urine. These findings suggest that DMLE exerts antihyperuricemic and uricosuric effects on promoting UA excretion by enhanced secretion and inhibition of UA reabsorption in the kidneys. Thus, DMLE may be a potential treatment for hyperuricemia and gout.
Collapse
|
5
|
Shen L, Gwak SR, Joo JC, Ha KC, Park YK, Kim S, Park SJ. Effectiveness and Safety of Hwangchil-Unripe Bokbunja Extract Mixture on Blood Pressure: A Randomized Double-Blind Placebo-Controlled Clinical Trial. J Med Food 2021; 24:258-266. [PMID: 33739883 DOI: 10.1089/jmf.2020.4820] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
From 25% to 50% of adults are affected by prehypertension. Prehypertension increases the risk of hypertension and affects the heart and systemic vascular system. Food mixed tree essence of Dendropanax morbifera called Hwangchil in Korean and immature fruit of Rubus coreanus, called Bokbunja (HDR-2), have been studied for safety and effectiveness against prehypertension studies. This study was a randomized double-blind placebo-controlled multicenter clinical trial lasting 19 months from October 2017 to May 2019. The 88 subjects who enrolled in the study were divided into two groups. The treatment group was provided HDR-2 and the other group took a placebo. Both HDR-2 and placebo were in the form of capsules, and the dose was 900 mg per day. Subjects took HDR-2 or placebo capsules once a day for 8 weeks before dinner. The primary observational indicators were systolic blood pressure (SBP) and diastolic blood pressure (DBP), and the secondary observational indicators were mean arterial pressure (MAP), mean pulse pressure, pulse rate, angiotensin-converting enzyme activity, renin activity, aldosterone, and highly sensitive-C reactive protein. The number of measurements was three times: the first visit in the screening week, the second visit in 4 weeks, and the third visit was after 8 weeks. Significant study results showed that the SBP and MAP of the HDR-2 group after 8 weeks were lower than those of the placebo group. Adverse events were not significantly different between the two groups. In conclusion, these results suggest that HDR-2 may be a useful intervention for the management of prehypertension. The protocol was registered in the Korean Clinical Trial Registration system (http://cris.nih.go.kr; registration number: KCT0004300).
Collapse
Affiliation(s)
- Lei Shen
- Department of Sasang Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan, Korea
| | - Si Ra Gwak
- Department of Sasang Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan, Korea
| | - Jong Cheon Joo
- Department of Sasang Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan, Korea
| | - Ki Chan Ha
- Healthcare Claims and Management Incorporation, Jeonju, Korea
| | - Yu Kyung Park
- Healthcare Claims and Management Incorporation, Jeonju, Korea
| | - Sunoh Kim
- B&Tech Co., Ltd., R&D Center, Gwangju, Korea
| | - Soo Jung Park
- Department of Sasang Constitutional Medicine, College of Korean Medicine, Woosuk University, Jeonju, Korea
| |
Collapse
|
6
|
Kim KJ, Jeong ES, Lee KH, Na JR, Park S, Kim JS, Na CS, Kim YR, Kim S. Unripe Rubus coreanus Miquel Extract Containing Ellagic Acid Promotes Lipolysis and Thermogenesis In Vitro and In Vivo. Molecules 2020; 25:molecules25245954. [PMID: 33339214 PMCID: PMC7766442 DOI: 10.3390/molecules25245954] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 12/15/2020] [Accepted: 12/15/2020] [Indexed: 02/06/2023] Open
Abstract
Previously, we demonstrated that a 5% ethanol extract of unripe Rubus coreanus (5-uRCK) and ellagic acid has hypocholesterolemic and antiobesity activity, at least partially mediated by the downregulation of adipogenic and lipogenic gene expression in high-fat diet (HFD)-fed animals. The present study investigated the thermogenic and lipolytic antiobesity effects of 5-uRCK and ellagic acid in HFD-induced obese C57BL/6 mice and explored its mechanism of action. Mice fed an HFD received 5-uRCK or ellagic acid as a post-treatment or pretreatment. Both post-treated and pretreated mice showed significant reductions in body weight and adipose tissue mass compared to the HFD-fed mice. The protein levels of lipolysis-associated proteins, such as adipose triglyceride lipase (ATGL), phosphorylated hormone-sensitive lipase (p-HSL), and perilipin1 (PLIN1), were significantly increased in both the 5-uRCK- and ellagic acid-treated mouse epididymal white adipose tissue (eWAT). Additionally, thermogenesis-associated proteins, such as peroxisome proliferator-activated receptor α (PPARα), carnitine palmitoyl transferase-1 (CPT1), uncoupling protein 1 (UCP1), and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α), in inguinal white adipose tissue (ingWAT) were clearly increased in both the 5-uRCK- and ellagic acid-treated mice compared to HFD-fed mice. These results suggest that 5-uRCK and ellagic acid are effective for suppressing body weight gain and enhancing the lipid profile.
Collapse
Affiliation(s)
- Kyeong Jo Kim
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., Gwangju 61239, Korea; (K.J.K.); (E.-S.J.); (K.H.L.); (J.-R.N.); (S.P.); (J.S.K.)
- College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Korea
| | - Eui-Seon Jeong
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., Gwangju 61239, Korea; (K.J.K.); (E.-S.J.); (K.H.L.); (J.-R.N.); (S.P.); (J.S.K.)
| | - Ki Hoon Lee
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., Gwangju 61239, Korea; (K.J.K.); (E.-S.J.); (K.H.L.); (J.-R.N.); (S.P.); (J.S.K.)
| | - Ju-Ryun Na
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., Gwangju 61239, Korea; (K.J.K.); (E.-S.J.); (K.H.L.); (J.-R.N.); (S.P.); (J.S.K.)
| | - Soyi Park
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., Gwangju 61239, Korea; (K.J.K.); (E.-S.J.); (K.H.L.); (J.-R.N.); (S.P.); (J.S.K.)
| | - Jin Seok Kim
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., Gwangju 61239, Korea; (K.J.K.); (E.-S.J.); (K.H.L.); (J.-R.N.); (S.P.); (J.S.K.)
| | - Chang-Su Na
- College of Korean Medicine, Dongshin University, Naju-si, Jeollanam-do 58245, Korea;
| | - Young Ran Kim
- College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Korea
- Correspondence: (Y.R.K.); (S.K.); Tel.: +82-(62)-528-2201 (S.K.); Fax: +82-(62)-528-2202 (S.K.)
| | - Sunoh Kim
- Central R&D Center, Bioresources and Technology (B&Tech) Co., Ltd., Gwangju 61239, Korea; (K.J.K.); (E.-S.J.); (K.H.L.); (J.-R.N.); (S.P.); (J.S.K.)
- Correspondence: (Y.R.K.); (S.K.); Tel.: +82-(62)-528-2201 (S.K.); Fax: +82-(62)-528-2202 (S.K.)
| |
Collapse
|